Pylarify (piflufolastat F18) injection
Ended Awarded Last action
- Contract number
- 36C25224F0098
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $802,710
Award facts
- Contract value 100% obligated
- $802,745.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$41,731 | |
| Supplemental Agreement for work within scope | $324,785 | |
| Supplemental Agreement for work within scope | -$14,985 | |
| Original award | $534,640 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging Inc., was awarded a delivery order valued at $802,745.68 by the Department of Veterans Affairs' Veterans Integrated Service Network 12 for the supply of PYLARIFY (piflufolastat F-18) injection. This firm fixed-price contract, awarded on February 1, 2024, with an ultimate completion date of October 21, 2025, is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside designation. The performance location is North Billerica, Massachusetts. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer, supporting critical diagnostic capabilities across VA medical facilities.
This delivery order represents a continuation of Progenics Pharmaceuticals' established federal supply relationship with the VA, which maintains several significant Indefinite Delivery Vehicles with the contractor through various Veterans Integrated Service Networks. The company serves as a key supplier of specialized radiopharmaceuticals to federal healthcare providers, including the VA, Defense Health Agency, and NIH Clinical Center. The firm fixed-price structure ensures cost stability for the government while enabling efficient procurement of this essential medical imaging product to support oncology diagnostic programs across the VA healthcare system.
Quick answers
Who was awarded contract 36C25224F0098?
36C25224F0098 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on February 1, 2024.
How much is contract 36C25224F0098 worth?
The government has obligated $802,710 on 36C25224F0098. Its current value, with exercised options, is $802,746.
Is contract 36C25224F0098 an order under another contract?
Yes. 36C25224F0098 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25224F0098 competed?
The extent of competition for 36C25224F0098 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award